04:51 PM EDT, 09/12/2024 (MT Newswires) -- Cidara Therapeutics ( CDTX ) said late Thursday it is cutting 30% of its workforce to substantially reduce capital needs and to focus on the development of CD388, its drug candidate for influenza A and B.

The company said that business development discussions continue for its oncology programs, including CBO421.

Cidara shares were about 4% lower in after-hours activity following a brief trading halt.

Price: 10.90, Change: -0.45, Percent Change: -3.96